Philadelphia University + Thomas Jefferson University

Looking Ahead: Perspectives on Ebola

Jefferson Hosts Ivory Coast Ambassador on 9/22

Research on an Ebola vaccine is being conducted right here at the Jefferson Vaccine Center. Other speakers joining His Excellency Daouda Diabate at the event are Professor E. Solange Ngazoa Kakou, PhD, of the Pasteur Institute of Ivory Coast, in addition to Jefferson’s Stephen Klasko, MD, MBA, Ebola vaccine researcher Matthias J. Schnell, PHD, and Kathleen E. Squires, MD. Register via email at

Ebola (Ebola hemorrhagic fever -- also known as Ebola HF) is a crisis in Africa. Research on a vaccine for the severe disease – which is often fatal in humans and nonhuman primates -- is being conducted right here at Jefferson’s Vaccine Center. Learn more about the research and hear speakers from both our institution, as well as from Ivory Coast, Africa.

Event Overview
Looking Ahead: Perspectives on Ebola
Monday, September 22

Hamilton Building, Connelly Auditorium, 3 p.m. – 5:15 p.m.
Reception to follow

Featured Speakers:

  • Stephen K. Klasko, MD, MBA, President and CEO, TJU and Jefferson Health System
  • Matthias J. Schnell, PhD, Professor and Director Jefferson Vaccine Center
  • Kathleen E. Squires, MD, Professor of Medicine and Division Director, Infectious Diseases and Environmental Medicine
  • His Excellency, Daouda Diabate, Ivory Coast Ambassador to the US  
  • E. Solange Ngazoa Kakou, PhD, Professor of Microbiology, Pasteur Institute of Ivory Coast

Please register via email now at or call 215-503-4335.

About the Vaccine Research at Jefferson

By many estimates, an Ebola vaccine could be available in humans as early as next year. But will it be the right one? There are a number of vaccines in development and each is in a race to prove that it is most effective, safe and that it will protect the largest number of people. One promising Ebola vaccine is based on a human rabies virus vaccine and is being developed by Thomas Jefferson University in collaboration with the National Institutes of Health (NIH). This novel vaccine could not only help rein in the current epidemic in West Africa, but could be easily expanded and used if another filovirus strain started to spread.

The researchers plan to develop the vaccine into the type of antibody serum therapy used in the first US recipients in a platform that could deliver at least 2,000 doses of potentially life-saving serum per month.

“Vaccines are the best way to completely eradicate an epidemic threat like Ebola,” said Matthias Schnell, PhD, Director of the Jefferson Vaccine Center and Professor of Microbiology and Immunology at Thomas Jefferson University. “But for those patients who already have the disease, antibody-based therapies could be the best treatment -- it’s a way to give the body’s own defenses time to ramp up.”

Dr. Schnell and his team have developed a vaccine that activates the immune system to produce large amounts of antibodies against three virus strains, in order to most effectively eradicate the threat of hemorrhagic fever. It includes the Zaire strain of Ebola virus that is currently spreading across West Africa, as well as the Sudan strain, and the Marburg virus, a virus in the same family as Ebola, which causes a very similar disease.

Learn more about the RESEARCH.